Bio-Techne has been granted a patent for mutant TcBuster transposases that exhibit increased transposition efficiency. These mutants have an amino acid sequence at least 70% identical to a specified sequence and include substitutions that enhance their net charge at neutral pH. GlobalData’s report on Bio-Techne gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Bio-Techne, Peptide pharmacophores was a key innovation area identified from patents. Bio-Techne's grant share as of July 2024 was 42%. Grant share is based on the ratio of number of grants to total number of patents.
Mutant tcbuster transposase with increased transposition efficiency
The patent US12037611B2 describes a novel mutant TcBuster transposase characterized by an amino acid sequence that is at least 70% identical to the full-length sequence identified as SEQ ID NO: 1. This mutant transposase features one or more amino acid substitutions that enhance its net charge at neutral pH compared to the wild-type TcBuster transposase. Specific substitutions mentioned include D99A, E247K, and E469K, which contribute to increased transposition efficiency. The claims further detail various combinations and locations of these substitutions, including those within critical domains such as DNA binding, oligomerization, and catalytic domains, thereby enhancing the functionality of the transposase in genetic applications.
Additionally, the patent outlines a system for genome editing that incorporates the mutant TcBuster transposase along with a transposon that it can recognize. The claims also encompass fusion transposases that combine the mutant TcBuster transposase with DNA sequence-specific binding domains, such as TALE or zinc finger domains. Methods for genome editing using this mutant transposase are also described, particularly emphasizing its application in primary cells, including those isolated from subjects with cancer or tumors. The comprehensive nature of these claims highlights the potential of the mutant TcBuster transposase in advancing genetic engineering and therapeutic strategies.
To know more about GlobalData’s detailed insights on Bio-Techne, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.
